• Adagene outlined ADG126 (muzastotug), a masked anti-CTLA-4 with FDA Fast Track designation, positioned as a potential best-in-class program.
• Reported positive interim efficacy with minimal discontinuations in late-line MSS colorectal cancer patients without liver metastases; targeted 3L+ market opportunity above USD 1 billion.
• Sanofi backing includes up to USD 25 million equity investment; support for a randomized phase 2 ADG126-pembrolizumab trial in advanced MSS CRC without liver metastases.
• Incyte to sponsor a phase 1 combination study of ADG126 with INCA33890 in 3L MSS CRC, expected to begin in 2026.
• Cash balance about USD 128 million as of June 30, 2026; runway projected into late 2028.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adagene Inc. published the original content used to generate this news brief on July 07, 2026, and is solely responsible for the information contained therein.